A multi-district lawsuit now before a Philadelphia judge brings critical scrutiny to popular GLP-1 weight loss medications. More than 130 cases allege these drugs are linked to non-arteritic anterior ischemic optic neuropathy, or NAION, which is a condition involving permanent vision loss. The legal action targets manufacturers Novo Nordisk and Eli Lilly, makers of Wegovy, Ozempic, Mounjaro, and Zepbound.
Legal filings and medical research serve as the foundation for these claims. A 2024 study published in JAMA Ophthalmology suggests that diabetic patients taking GLP-1 medications face a higher probability of NAION diagnosis, with even higher rates observed in overweight patients. This condition involves restricted blood flow to the optic nerve, resulting in sudden and irreversible sight loss.
Plaintiffs describe their experiences as life-altering. Diane Wirth, a former nurse practitioner and plaintiff, reported sudden vision loss in one eye after being prescribed Wegovy. She and other plaintiffs argue that had they been aware of potential vision risks, they would have declined the treatment. Attorneys representing the plaintiffs emphasize that the condition often strikes without warning, leaving patients with no way to predict or prevent the damage.
In response to the lawsuits, drug manufacturers maintain their commitment to patient safety. Eli Lilly stated that current evidence does not establish a causal link between their products and the condition, noting they continue to monitor safety data alongside regulators. Novo Nordisk also referenced its own internal study of 96,000 patients, which indicated no increased risk of NAION.
The debate highlights differences in international drug labeling. While some European and UK labels have been updated to warn about the condition, domestic labels currently do not feature the same language. The Centers for Disease Control and Prevention now recommends that patients using GLP-1 medications consult an ophthalmologist to establish a baseline vision examination. As the legal proceedings move forward, the case highlights the tension between the widespread adoption of these weight loss treatments and the emergence of potential side effects.